http://www.youtube.com/watch?v=jO_lNh-SCis
It’s only been a few months since GlaxoSmithKline (NYSE: GSK) launched a $50 million fund to invest in life science industries developing bioelectronic technology. Now, it has kicked off an innovation challenge to crowdsource the technology. Specifically, it’s looking for an implantable device that can interpret and “write” the body’s electrical signals.
Not only is it a competition, it’s also a race. Here’s a brief description:
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“The prize will be awarded to scientists who are first able to solve the challenge of creating a miniaturized, fully implantable device that can read, write and block the body’s electrical signals to treat disease. It is hoped that finding a solution to this challenge will open and accelerate significant avenues of research in this field.”
How many scientists does it take to devise a challenge like this? Apparently, 150. It was part of the work they did at a Bioelectronic Medicines Summit in New York, organized by GSK’S Bioelectronics R&D unit. They see the development of this implantable device as a critical piece to help make the development of bioelectronic therapeutics part of the future of healthcare.
